Fifth Third Bancorp Lowers Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Fifth Third Bancorp trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 25.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,777 shares of the medical research company's stock after selling 3,752 shares during the period. Fifth Third Bancorp's holdings in Charles River Laboratories International were worth $1,989,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Empirical Finance LLC grew its stake in shares of Charles River Laboratories International by 4.2% during the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company's stock valued at $258,000 after buying an additional 53 shares during the last quarter. American Trust boosted its holdings in Charles River Laboratories International by 5.9% during the 2nd quarter. American Trust now owns 976 shares of the medical research company's stock valued at $202,000 after acquiring an additional 54 shares during the period. OLD National Bancorp IN grew its position in Charles River Laboratories International by 3.1% during the 3rd quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company's stock worth $392,000 after acquiring an additional 59 shares during the last quarter. Fiduciary Financial Group LLC increased its stake in Charles River Laboratories International by 3.9% in the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock worth $310,000 after purchasing an additional 63 shares during the period. Finally, Pinnacle Bancorp Inc. lifted its position in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after purchasing an additional 65 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Insider Activity at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now owns 12,386 shares of the company's stock, valued at $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Redburn Atlantic initiated coverage on shares of Charles River Laboratories International in a research note on Monday, October 14th. They issued a "sell" rating and a $151.00 target price on the stock. UBS Group reiterated a "neutral" rating and issued a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Evercore ISI increased their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an "in-line" rating in a research note on Thursday, November 7th. Bank of America reduced their target price on Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating on the stock in a report on Friday, December 13th. Finally, TD Cowen raised their target price on Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research note on Monday, November 11th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $204.38.

Charles River Laboratories International Price Performance

Shares of CRL stock traded down $2.23 during mid-day trading on Tuesday, hitting $163.61. The company had a trading volume of 533,889 shares, compared to its average volume of 987,529. The company has a market capitalization of $8.37 billion, a P/E ratio of 20.48, a P/E/G ratio of 5.94 and a beta of 1.38. The stock's 50 day moving average price is $185.87 and its 200-day moving average price is $196.49. Charles River Laboratories International, Inc. has a 52-week low of $160.85 and a 52-week high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $975.99 million. During the same quarter in the previous year, the company posted $2.72 EPS. The company's revenue was down 1.6% compared to the same quarter last year. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).